Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes marketed products and several other assets in various stages of clinical development and across a range of research areas: immuno-oncology, tropomyosin receptor kinase signaling, oncogenic signaling, DNA damage response, antibody-drug conjugates, alpha radiopharmaceuticals, and androgen receptor signaling.

Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.